期刊文献+

炎性因子及外周血指标与子宫内膜癌诊治及预后相关性研究进展 被引量:5

Research Progress of the Relationship of Inflammatory Factors and Peripheral Blood Indexes with the Diagnosis,Treatment and Prognosis of Endometrial Carcinoma
下载PDF
导出
摘要 子宫内膜癌(EC)是在世界范围内发病率较高的妇科恶性肿瘤之一。近年来,人们认识到,癌症患者的诊断及治疗并不完全由癌症的特征决定,而体循环和肿瘤微环境中与肿瘤相关的各种指标也可能是癌症发生和进展的关键因素。其中炎性因子、中性粒细胞、淋巴细胞、血小板及其之间的比值是简单、容易获取且较稳定的临床指标,这些指标已在多种癌症中得到广泛研究。炎性因子和外周血相关指标与EC的发生、发展具有相关性,联合运用相关指标有利于EC的早期诊断及治疗,如何联用炎性因子和外周血相关指标并提高诊断EC的敏感性和特异性是未来研究的重点。 Endometrial carcinoma (EC) is one of the gynecological malignant tumors of high incidence worldwide. In recent years, it's realized that the diagnosis and treatment of cancer patients is not entirely determined by the characteristics of cancer, and various indexes in tumor related systemic circulation and microenvironment may also be key factors in the progression of cancer. Among them, inflammatory factors, neutrophils, lymphocytes, platelets and their ratio are simple, easy to obtain and stable clinical indicators, which have been widely studied in a variety of cancers. There is a correlation between the development of relevant indicators of inflammation and peripheral blood and EC, the combination of which is helpful for the early diagnosis and treatment for EC, and how to combine the related indicators of peripheral blood and inflammatory cytokines to improve the sensitivity and specificity of diagnosis of EC is the focus of the future research.
出处 《医学综述》 2017年第24期4840-4845,共6页 Medical Recapitulate
关键词 子宫内膜癌 炎性因子 外周血液指标 诊治 预后 Endometrial cancer Inflammatory factors Peripheral blood indexes Diagnosis and treatment Prognosis
  • 相关文献

参考文献3

二级参考文献20

  • 1Poveda A, Gonzalez-Martin A. Multimodality treatment in locore-gional gynecological cancer: cervical cancer treatment update[J]. Ann Oncol, 2008, 19(Suppl 7):vii70-76.
  • 2Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally ad-vanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial[J]. Lan-cet Oncol, 2012, 13(1):25-32.
  • 3Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer [J]. J Gynecol Oncol, 2012, 23(4):265-273.
  • 4Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of an-ti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):2455-2465.
  • 5Voloshin T, Voest EE, Shaked Y. The host immunological response to cancer therapy: An emerging concept in tumor biology[J]. Exp Cell Res, 2013, 319(11):1687-1695.
  • 6Majeti BK, Lee JH, Simmons BH, et al. VEGF is an important me-diator of tumor angiogenesis in malignant lesions in a genetically en-gineered mouse model of lung adenocarcinoma[J]. BMC Cancer, 2013, 13(1):213.
  • 7Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung can-cer associated with treatment response and prognosis[J]? Asian Pac J Cancer Prev, 2013, 14(9):5237-5242.
  • 8Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocy-tosis in ovarian cancer[J]. N Engl J Med, 2012,366(7):610-618.
  • 9Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte num-ber has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer[J]. Radiat Oncol, 2010, 5:47.
  • 10Choi CH, Kang H, Kim WY, et al. Prognostic value of baseline lym-phocyte count in cervical carcinoma treated with concurrent chemo-radiation[J]. Int J Radiat Oncol Biol Phys, 2008, 71(1):199-204.

共引文献37

同被引文献40

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部